- Home
- Companies
- canada quebec
- immune evasion
Refine by
Immune Evasion Suppliers Serving Quebec
4 companies found
based inHercules, CALIFORNIA (USA)
Bio-Rad is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for 70 years, our products ...
The dengue virus (DENV), first isolated in 1943, is assigned to the family Flaviviridae, genus Flavivirus. It has four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) and transmission to humans occurs via the Aedes mosquito, mainly Aedes aegypti. Its ...
based inPaddington, AUSTRALIA
Regeneus is an Australian biotechnology company aiming to improve the quality of life of the hundreds of millions of patients worldwide suffering from long and short term pain. Pain and inflammation are responsible for a series of events leading to ...
Progenza is a cryopreserved multi-synergistic therapy targeting pain and inflammation. Regeneus has patented techniques and high-quality testing to ensure the production of millions of Progenza™ doses from a single donor ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
N-Nitroso-N-methylurea (NMU;MNU;NMH) is a potent carcinogen, mutagen and teratogenand. N-Nitroso-N-methylurea is a direct-acting alkylating agent that interacts with DNA. N-Nitroso-N-methylurea targets multiple animal organs to cause various cancer ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to ...